uniQure N.V. to announce Q2 2026 financial results on July 29
uniQure N.V. will release its Q2 2026 financial results on July 29, 2026, followed by a management conference call at 8:30 a.m. ET. The call will be webcast and archived for 90 days, with analysts able to participate via dial-in. Investors will seek updates on the company's gene therapy pipeline, including treatments for Huntington's disease and hemophilia B.
*this image is generated using AI for illustrative purposes only.
uniQure N.V. will announce its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. The gene therapy company, focused on transformative treatments for severe medical needs, will host a conference call at 8:30 a.m. ET to review the performance. The announcement is critical for investors tracking the progress of uniQure's proprietary gene therapies for conditions such as Huntington's disease and hemophilia B.
Management will discuss the financial outcomes and operational updates during the call, which will be webcast live under the Events & Presentations section of uniQure’s website. A replay of the event will be archived and accessible for 90 days, providing stakeholders ample time to review the details.
Analysts interested in participating in the question-and-answer session can join the live call by dialing (646) 307-1963 or toll-free at (800) 715-9871. Participants must enter conference ID 5075555 and are advised to join 15 minutes before the start time to ensure connectivity.
uniQure's pipeline includes gene therapies for refractory temporal lobe epilepsy, Fabry disease, and other severe disorders. The company's recent approval of a gene therapy for hemophilia B marked a significant milestone in genomic medicine. Investors will be looking for updates on these programs during the upcoming call.
Conference Call Details
| Detail | Information |
|---|---|
| Date | July 29, 2026 |
| Time | 8:30 a.m. ET |
| Webcast | uniQure website Events & Presentations section |
| Replay Availability | 90 days |
| Dial-in (US) | (646) 307-1963 |
| Toll-free Dial-in | (800) 715-9871 |
| Conference ID | 5075555 |
What are the expected revenue projections from the recently approved hemophilia B gene therapy?
How will the clinical trial progress for Huntington's disease impact the company's valuation?
What strategic partnerships might uniQure pursue to accelerate the development of its pipeline therapies?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
